—
C+
C+ The full Closelook — membership. Open the C+ overview

Bristol-Myers Squibb Company (BMY) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Bristol-Myers Squibb Company

BMY in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Bristol-Myers Squibb researches, makes and sells prescription medicines worldwide, covering cancer, blood disorders, immune disease, heart disease and brain conditions. Its portfolio spans older blockbuster drugs such as Eliquis and Revlimid alongside newer immuno-oncology and cell-therapy treatments like Opdivo and Breyanzi, plus recent launches in psoriasis, schizophrenia and lung cancer. It sells through wholesalers, distributors, specialty pharmacies, hospitals and government agencies rather than directly to patients.
Where it sits in the stack
Bristol-Myers Squibb carries no seat in our Rubin AI build-out index; it sits in the diary's broader universe under Healthcare, in the drug manufacturing sleeve alongside other large branded pharmaceutical makers.
Who it is priced against
Closelook's peer group is not defined for this name; the market commonly compares it with Pfizer and Merck as fellow diversified branded-drug makers.
Why Closelook tracks it
Bristol-Myers Squibb is an S&P 500 constituent but holds no Closelook score yet and no Rubin or Halo seat; the diary has not quoted it in an edition so far.
What the diary watches
Whether revenue from newer oncology and immunology launches grows fast enough to offset the older drugs in the portfolio losing exclusivity.

Bristol-Myers Squibb Company (BMY) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: BMY news on the tape · index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BMY, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Piper Sandler, 2026-09-16

The Street on this name

Analyst actions and the latest print for BMY from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Piper Sandler — target 82 from 75 Target raised to $82 from $75 (+28.7% to spot) 2026-09-16

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BMY on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Bristol-Myers Squibb Company (BMY)?

Bristol-Myers Squibb Company trades as BMY on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is BMY in a Closelook index?

Not currently — Bristol-Myers Squibb Company is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does BMY trade against its moving averages?

Pullback inside an uptrend stack: Trades -1.7% vs the 50-day and +7.5% vs the 200-day average, 8.4% below the 52-week high and +51.1% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Bristol-Myers Squibb Company do?

Bristol-Myers Squibb researches, makes and sells prescription medicines worldwide, covering cancer, blood disorders, immune disease, heart disease and brain conditions. Its portfolio spans older blockbuster drugs such as Eliquis and Revlimid alongside newer immuno-oncology and cell-therapy treatments like Opdivo and Breyanzi, plus recent launches in psoriasis, schizophrenia and lung cancer. It sells through wholesalers, distributors, specialty pharmacies, hospitals and government agencies rather than directly to patients. Closelook's peer group is not defined for this name; the market commonly compares it with Pfizer and Merck as fellow diversified branded-drug makers.

Where does Bristol-Myers Squibb Company sit in the AI build-out?

Bristol-Myers Squibb carries no seat in our Rubin AI build-out index; it sits in the diary's broader universe under Healthcare, in the drug manufacturing sleeve alongside other large branded pharmaceutical makers. Bristol-Myers Squibb is an S&P 500 constituent but holds no Closelook score yet and no Rubin or Halo seat; the diary has not quoted it in an edition so far.

What has Wall Street done on Bristol-Myers Squibb Company recently?

The most recent analyst action on Bristol-Myers Squibb Company on the Closelook wire is a price target by Piper Sandler on 2026-09-16 (target 82 from 75). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BMY, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.